| Biomarker ID | 208 |
| PMID | 16618727 |
| Year | 2006 |
| Biomarker | COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489] |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Extracellular matrix organization,ECM-receptor interaction,ECM-receptor interaction,NCAM1 interactions, Syndecan 1 pathway |
| Experiment | Cancerous Tissue Vs Normal Tissue |
| Type of Biomarker | Diagnostic |
| Cohort | Two sets of Patients were included in the study. Set 1 included 10 cancerous, and 6 normal tissues. Set 2 included 12 cancerous and 10 normal tissues |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | 8.16E-06 |
| Method Used | RT-PCR and qPCR |
| Clinical | No |
| Remarks | Brackets indicate ISOFORMS of the mRNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | COL6A2 |